TY - JOUR AU - Antonarakis, Emmanuel S. PY - 2012 TI - Enzalutamide: the emperor of all anti-androgens JF - Translational Andrology and Urology; Vol 2, No 2 (June 16, 2013): Translational Andrology and Urology Y2 - 2012 KW - N2 - In the last few years, there has been a rekindled interest in the androgen receptor (AR) and AR signaling as valid therapeutic targets in prostate cancer. While the primary goal of therapy for recurrent or advanced prostate cancer has long been to reduce circulating and intratumoral androgen levels, recent laboratory and clinical data have shown that AR signaling remains active (and continues to drive tumor growth) even in the castration-resistant state (1). UR - https://tau.amegroups.org/article/view/1100